Propolis Intake by People Living With HIV: Biochemical Profile, Nutritional Status, and Safety

Abstract

Introduction: The antiretroviral therapy promotes alterations in the metabolic and nutritional profile contributing to the early development of non-AIDS comorbidities. In order to include new candidates to mitigate antiretroviral effects, this study aimed at investigating the effect of propolis on people living with HIV/AIDS (PLWHA) with sustained viral suppression. Methods: Forty PLWHA (20 propolis and 20 placebo) were enrolled in a randomized double-blind, placebo-controlled clinical trial. The effect of propolis daily intake (500 mg) on their biochemical and nutritional status was assessed before and after 3 months. The participant's dietary pattern was also registered. Results: Both groups were homogeneous regarding clinical and sociodemographic characteristics. An increased creatinophosphokinase (P = 0.011) was seen after propolis intake, not exceeding the standard reference range, as well as an increased magnesium concentration (P = 0.003), which can contribute for maintaining the body's homoeostasis. The participants’ diet did not change during the intervention period. Conclusions: Propolis consumption did not affect the virological, nutritional, biochemical, or metabolic profile after 3 months, indicating that the daily intake of propolis was safe for asymptomatic PLWHA on antiretroviral therapy.